Carbamazepine (Epilepsy)

Hypospadias

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5483
R15647		 Bànhidy (Carbamazepine), 2011 Hypospadias throughout pregnancy case control unexposed, sick Adjustment: No Matched 0.33 [0.03;3.78] C 1/11   3/13 4 11
ref
S8411
R26712		 Jentink (Carbamazepine), 2010 Hypospadias 1st trimester case control unexposed (general population or NOS) Adjustment: Yes 0.70 [0.30;1.60] 6/-   -/- - -
ref
Total 2 studies 0.65 [0.29;1.43] 4 11
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bànhidy (Carbamazepine), 2011Bànhidy, 2011 1 0.33[0.03; 3.78]41111%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Jentink (Carbamazepine), 2010Jentink, 2010 2 0.70[0.30; 1.60]--89%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 0.65[0.29; 1.43]4110.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine; 2: Carbamazepine;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 0.65[0.29; 1.43]4110%NABànhidy (Carbamazepine), 2011 Jentink (Carbamazepine), 2010 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.70[0.30; 1.62]-- -NAJentink (Carbamazepine), 2010 1 unexposed, sickunexposed, sick 0.33[0.03; 3.78]411 -NABànhidy (Carbamazepine), 2011 1 Tags Adjustment   - No  - No 0.33[0.03; 3.78]411 -NABànhidy (Carbamazepine), 2011 1   - Yes  - Yes 0.70[0.30; 1.62]-- -NAJentink (Carbamazepine), 2010 1 MatchedMatched 0.33[0.03; 3.78]411 -NABànhidy (Carbamazepine), 2011 1 All studiesAll studies 0.65[0.29; 1.43]4110%NABànhidy (Carbamazepine), 2011 Jentink (Carbamazepine), 2010 20.110.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.07[0.25; 17.50]-1444%NAJentink (Carbamazepine), 2010 D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 Van der Pol (Carbamazepine) (Controls unexposed, disease free), 1991 3 unexposed, sick controlsunexposed, sick controls 0.76[0.12; 4.89]4250%NABànhidy (Carbamazepine), 2011 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 Van der Pol (Carbamazepine) (Controls unexposed, sick), 1991 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.34[0.48; 3.71]324,64739%NATomson (Carbamazepine), 2018 Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 Hernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012 30.510.01.0